Healthcare
Live Price
Offline$10.24
+0.00% today
1Y Change
-3.17%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
DocMorris AG (ZRSEF) is a Healthcare stock with a market cap of $340.00M and listed on OTC. The stock last traded around $10.24 and down 3.2% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +10.6%, EPS growth of +68.5%, a dividend yield of 0.0%. What stands out right now is revenue +10.6%, EPS +68.5%, free cash flow -63.2% with operating margin -7.5% and ROIC -11.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.3. Stock Foundry combines ZRSEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZRSEF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZRSEF Max Drawdown
-3.17%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZRSEF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.7B
+85.5% YoY
FY Net Income
-$225.7M
-31.9% YoY
Free Cash Flow
-$194.1M
-24.0% YoY
Revenue Growth
+10.6%
EPS Growth
+68.5%
Gross Margin
9.4%
Net Margin
-12.0%
Income statement
CHF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 1.0B | 969M | 931M | 1.7B |
| Gross Profit | 106M | 217M | 203M | 160M | 260M |
| Operating Income | -84M | -104M | 90M | 40M | 107M |
| EBITDA | -39M | -38M | -56M | -112M | -178M |
| Net Income | -134M | -97M | 82M | -171M | -226M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CHF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 120M | 95M | 54M | 126M | 278M |
| Total Assets | 826M | 778M | 866M | 1.1B | 1.3B |
| Total Liabilities | 417M | 438M | 436M | 749M | 784M |
| Shareholder Equity | 409M | 340M | 431M | 351M | 485M |
| Total Debt | 289M | 312M | 331M | 529M | 525M |
| Net Debt | 169M | 217M | 277M | 403M | 247M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
131M
-34.3% YoY
Capital Expenditures
63M
-7.1% YoY
Free Cash Flow
194M
-24.0% YoY
Key ratios
Gross Margin
9.4%
Operating Margin
-7.5%
Net Margin
-12.0%
ROE
-30.2%
Debt / Equity
0.71x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.